details

Eleven lectures by 15 speakers / Focus on advances in diagnostics and therapy / Training event for scientists and physician

The National Center for Tumor Diseases (NCT) Heidelberg is hosting its 35th Spring Symposium on February 3, 2018. This year’s event is about "Current Developments in the Diagnosis and Therapy of Gastrointestinal Tumors“ and takes place at the communication center at the German Cancer Research Center (DKFZ). The invitation is addressed exclusively to scientists, physicians and medical professionals. The State Medical Association recognizes the event as further education. Registration is requested.

The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, the Heidelberg University Hospital and the German Cancer Aid.

"Gastrointestinal tumors are very important because of their frequent occurrence and often place high demands on interdisciplinary cooperation," says Dirk Jäger, Managing Director and Head of Medical Oncology at the NCT Heidelberg, in regard to this year's theme of the Spring Symposium. "Thanks to the recent progress in diagnosis and therapy of gastrointestinal tumors, for example in the field of immunotherapy, more patients can be helped and more can be achieved in palliative situations." For this reason, the aim of this year's symposium is to present the most important practical advances in immunotherapy, molecular characterization, radiotherapy and surgical procedures in a compact form.

The event will start on the 3rd of February at 9 am, the end is scheduled for 1:30 pm. Afterwards, the NCT invites you to a culinary finale. In a total of eleven lectures, 15 speakers from the NCT, Heidelberg University Hospital and the DKFZ report on the current state of diagnostics and therapy for gastrointestinal tumors. The Medical Chamber Baden-Württemberg awards five further education credits for participation. The Spring Symposium will take place in the large auditorium at the communication center of the German Cancer Research Center (DKFZ) in Heidelberg. The event is not public and is aimed at scientists and physicians as well as medical professionals. Participants can register until 2 February by phone (06221/56 65 58), by fax (06221/56 50 94), online at www.nct-heidelberg.de/anmeldung or by e-mail to hso@nct-heidelberg.de.

The flyer for the event can be downloaded at:
www.nct-heidelberg.de/fileadmin/media/news/Meldungen/Dateien/Fruehjahrssymposium_Flyer_2_.pdf

Press contacts:

Dr. Friederike Fellenberg
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
E-Mail: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Doris Rübsam-Brodkorb
Universitätsklinikum Heidelberg und Medizinische Fakultät der Universität Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
E-Mail: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de

Dr. Sibylle Kohlstädt
Deutsches Krebsforschungszentrum (DKFZ)
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
E-Mail: s.kohlstaedt@dkfz.de
www.dkfz.de

The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. 2015 the NCT Heidelberg established a partner location in Dresden.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital and Medical Faculty Heidelberg
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 12 600 individuals and are involved in training and qualification. Every year approximately 66 000 patients are treated as inpatients or day patients in more than 50 specialized clinical departments with about 1 900 beds, with more than 1 million patients being treated as outpatients. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present approx. 3500 prospective physicians are studying in Heidelberg.